ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Meta-analysis adds evidence to association between omega-3 supplementation and lower heart rate

Friendly User's Guide for the Timing of Nutritional Supplements

The Health Benefits of Manuka Honey

Increase Your Magnesium Intake

Vitamin D supplementation could ease IBS symptoms

Top Tips to Boost Your Immunity

Essential Oils Lower Blood Pressure

11 Amazing Health Benefits of Using Baking Soda

Nicotinamide riboside shows promise for treatment of Alzheimer’s disease

Exercise, calcium, vitamin D, and other factors linked with fewer injurious falls

Print Page
Email Article

FDA Approves ENBREL as First Therapy to Inhibit Bone and Joint Damage In Psoriatic Arthritis Patients

  [ 177 votes ]   [ Discuss This Article ] • August 26, 2003

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Aug. 25 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved an expanded indication for ENBREL(R) (etanercept) to inhibit the progression of structural damage of active arthritis in patients with psoriatic arthritis. The approval is being announced today by Amgen (Nasdaq: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).

ENBREL is the first and only approved therapy for both the inhibition of structural damage and the reduction in signs and symptoms of patients with psoriatic arthritis.

"This is the first time a large clinical trial has demonstrated inhibition of radiographic progression of joint damage in people with psoriatic arthritis," says Willard Dere, M.D., Vice President of Clinical Development for Amgen. "These data underscore the benefits of treating psoriatic arthritis patients with ENBREL."

Approval was based on a phase 3 study evaluating 205 patients with active psoriatic arthritis. ENBREL demonstrated inhibition of joint damage over a one-year study period, while x-rays of patients receiving a placebo showed progressive joint destruction.

"ENBREL has now been shown to inhibit underlying joint damage in two
distinct diseases, rheumatoid arthritis, and now, psoriatic arthritis", says Victoria Kusiak, M.D., Vice President of Global Medical Affairs and North American Medical Director of Wyeth Pharmaceuticals. "As with rheumatoid arthritis, treatment with ENBREL can improve the painful and debilitating symptoms of psoriatic arthritis. "

Adverse events were similar to those reported in previous clinical trials of ENBREL in patients with rheumatoid arthritis. There was no increase in the number of serious adverse events occurring in patients treated with ENBREL compared to those receiving placebo. Only the rate of injection site reactions (ISRs) in patients receiving ENBREL was statistically different compared to those receiving placebo (36 percent with ENBREL versus 9 percent in placebo-treated patients).


Psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease combines joint pain and swelling that can lead to crippling debilitation with inflamed and irritated scaly red patches of skin on the body. The disease can be difficult to diagnose, particularly in its milder forms and earlier stages. Up to one million people in the U.S. population have psoriatic arthritis.


ENBREL is the only fully human anti-TNF receptor approved to reduce signs and symptoms, improve physical function, and inhibit structural damage in patients with moderately to severely active rheumatoid arthritis (RA), and to reduce the signs and symptoms and inhibit the progression of structural damage in patients with active psoriatic arthritis. ENBREL is the only biologic therapy approved for first-line treatment of RA patients, and can be used in combination with methotrexate or alone. It is approved to reduce the signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis (JRA) in patients who have had an inadequate response to disease-modifying medicines. It is also the first biologic approved to treat the signs and symptoms in patients with active ankylosing spondylitis (AS).

The benefits and long-term tolerability profile of ENBREL have been
established in the treatment of over 180,000 patients worldwide across all indications.

ENBREL acts by binding TNF, one of the dominant inflammatory cytokines or regulatory proteins that play an important role in both normal immune function and the cascade of reactions that causes the inflammatory process of psoriatic arthritis, RA and AS. The binding of ENBREL to TNF renders the bound TNF biologically inactive, resulting in significant reduction in inflammatory activity.

Since the product was first introduced, the following have been reported in patients using ENBREL:

* Serious Infections

-- Many occurred in people prone to infection, such as those with
advanced or poorly controlled diabetes

-- Some serious infections were fatal

-- Rare cases of tuberculosis

* What to do / Not do

-- Do not start ENBREL if you have an infection or are allergic to
ENBREL or its components

-- Tell your doctor if you are prone to infection

-- Stop ENBREL if a serious infection occurs

-- Contact your doctor if you have questions about ENBREL or develop
an infection

* Serious nervous system disorders such as multiple sclerosis, seizures,or inflammation of the nerves of the eyes.

-- Tell your doctor if you have ever had any of these disorders or if
you develop them after starting ENBREL

* Rare reports of serious blood disorders (some fatal)

-- Contact your doctor immediately if you develop symptoms such as
persistent fever, bruising, bleeding, or paleness

* The incidence of cancer has not increased with extended exposure to
ENBREL and is similar to the expected rate.

* ENBREL can also cause injection site reactions.

* In a medical study of patients with JRA, infections, headaches,
abdominal pain, vomiting, and nausea occurred more frequently than in adults.

-- The kinds of infections reported were generally mild and similar to those usually seen in children

-- Other serious adverse reactions were reported rarely, including
serious infections (two percent) and depression/personality disorder (one percent)

Amgen and Wyeth Pharmaceuticals, a division of Wyeth, market ENBREL in
North America. Wyeth markets ENBREL outside of North America. Immunex Corporation, a wholly owned subsidiary of Amgen, manufactures ENBREL.

Additional information about ENBREL, including full Prescribing Information, can be found on the Web site sponsored by the companies at or by calling toll free 888-4ENBREL (888-436-2735).

Post a Comment

Featured Products From the ProHealth Store
Ultra EPA  - Fish Oil Ultra ATP+, Double Strength Optimized Curcumin Longvida®

Article Comments

Be the first to comment on this article!

Post a Comment

Optimized Curcumin Longvida with Omega-3

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get Energized with Malic Acid & Magnesium
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery
Natural Bladder Control, Go Less and Live More Natural Bladder Control, Go Less and Live More
Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients
A Hard-Working Molecule that May Help Ease Pain & Brighten Mood A Hard-Working Molecule that May Help Ease Pain & Brighten Mood
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2018 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map